Samsung Biologics
207940.KS · Bio
World's largest contract biologics manufacturer (CDMO). Produces biosimilars and biologics for global pharma.
Latest news
"Organoids Over Rats": Mepsgen, Kangstem Target 7 Trillion Won Alternative Testing Market
Incheon City Council Opens, Vows to Boost Competitiveness With Bio, AI
Strike, Bonus Uncertainty Prompt Brokerages to Cut Samsung Biologics Target Price
K-Bio Faces Capital Drought Despite Global Spotlight
Samsung Biologics Q2 Earnings Unscathed Despite Strike
"Just Focus on Research": Inside Lilly Gateway Labs
Samsung Biologics Union Votes to Leave Samsung Group Super-Enterprise Union
Samsung Biologics Expands Reach With "Platform Export" Strategy
Samsung Biologics to Export Antibody, ADC Platform Technologies
BTGen to Invest National Growth Fund Backing in Plant Expansion, Pursue CDMO Process Edge
Samsung Biologics to Expand Supply Chain, Open European Sales Base
Samsung C&T Jumps 13% on Samsung Electronics Stake Value, Shareholder Return Hopes
Korea Sets Record 77 Booths at BIO USA as China Pivots to One-on-One Meetings
K-Bio Leverages AI to Partner With Big Pharma at BIO USA
Samsung Biologics Order Backlog Tops $10.4 Billion on Contract Expansions
Korean CDMOs Link Songdo to U.S. Plants in Global Race for Orders
K-Bio Heads to BIO USA, Seeking Deals and Tech Exports
Samsung Biologics to Attend BIO USA for 14th Consecutive Year
KOSPI Tops 8,000, But 52-Week Lows Outnumber Highs
D-7 to 'BIO USA': Korean Firms Mobilize for Licensing, CDMO Megadeals
1,508 Korean Stocks Hit Record Highs, but 1,763 Mark Lows
US Moves to Ease Clinical Trial Barriers, Opening Door for K-Bio
